PET imaging with copper-64 (Cu-64) DOTATATE could become a lower-radiation dose option for patients with suspected neuroendocrine tumors, according to the results of a phase III clinical trial published online January 10 in the Journal of Nuclear Medicine.
Source: Cu-64 DOTATATE PET could handle neuroendocrine tumors